Three biotech stocks to buy now

Professional investor Daniel Koller picks three cutting edge three biotech stocks to buy now.

A professional investor tells us where he'd put his money. This week: Daniel Koller of BB Biotech selects three biotech plays.

Investors have a vast array of markets and sectors to choose from, but biotechnology is one of the most fascinating and promising. The market has expanded by 560% in a decade and is expected to grow by around 10% a year over the next ten years. And an investment in biotechnology isn't just an opportunity to profit personally: you are also helping to fund cutting-edge science and bring forward the discovery of cures or treatments that have so far eluded the medical establishment.

Biotech companies are becoming more innovative in the battle against major physical and psychological disorders. New cell-therapy programmes (whereby healthy cells , such as T-cells capable of fighting cancer, are injected into patients) look particularly encouraging.

Pessimists, however, point to the highly charged political debate over drug prices and drug reimbursement programmes.At issue is the amount the insurer pays for the drug (depending on the type of drug, the insurer will pay the pharmacist or drug manufacturer directly). They think the cost of such programmes will stifle biotech companies' creativity, profitability and viability as insurers keen to save money baulk at the price of new treatments.

Solid pricing power

But biotechs' creativity, profitability and viability are consistent with high prices. If the drugs work, the firm has pricing power. If you look at biotech companies active in, say, cancer treatment, they have more leeway in setting prices as long as the products they bring to the market deliver superior medical benefits. Currently the unmet medical need in many cancer patients remains worryingly high. So companies whose drugs work best will be more competitive in the marketplace. This will rightly give them more flexibility in setting their prices.

On that note, consider Celgene (Nasdaq: CELG), which develops innovative cancer treatments. Analysts and medics keep a close eye on clinical data from Celgene and its partner Bluebird Bio when it comes to cell therapy in patients with bone-marrow cancer. This has been classified as "breakthrough therapy designation" by the US Food and Drug Administration, fast-tracking development of the new drug.

At the forefront of innovation

Biotech firms often experiment with brand-new technology. Akcea Therapeutics (Nasdaq: AKCA) works to transform the treatment of serious and rare diseases by making use of "RNA targeted" antisense technology, which essentially "turns off" a mutated gene. This is a notable breakthrough.

Sage Therapeutics (Nasdaq: SAGE) has made significant progress with a new drug to treat major depressive disorders and other problems with the central nervous system. It has now achieved the all-important phase III trial status (meaning a treatment is tested on a large sample of people). The US Food and Drug Administration has now approved expedited development for the drug, which could prove to be a major landmark in the treatment of depression.

These firms' innovations should prove lucrative despite the complex backdrop for medical funding. The future is as exciting for investors as it is hopeful for patients.

Recommended

Three safe bets on the growing online gambling sector
Share tips

Three safe bets on the growing online gambling sector

Professional investor Aaron Fischer, creator of the Fischer Sports Betting and iGaming ETF, picks three of his favourite online gambling stocks.
29 Nov 2021
Two outstandingly cheap UK stocks in an age of mad valuations
UK stockmarkets

Two outstandingly cheap UK stocks in an age of mad valuations

In these times of nutty company valuations, there is still plenty of opportunity around, says Merryn Somerset Webb. Take these two stocks, for example…
26 Nov 2021
Four of the best digital healthcare stocks to buy now
Share tips

Four of the best digital healthcare stocks to buy now

Thanks to Covid-19, policymakers and investors have become more aware of the wide array of opportunities in the sector. The good news is that we are a…
26 Nov 2021
Share tips of the week – 26 November
Share tips

Share tips of the week – 26 November

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
26 Nov 2021

Most Popular

Don’t worry about the global population explosion – it’s unlikely to happen
Investment strategy

Don’t worry about the global population explosion – it’s unlikely to happen

One of the many things we are taught to worry about is the fast-rising global population. But in fact, says Merryn Somerset Webb, the opposite is tru…
15 Nov 2021
Four of the best new investment trust listings
Investment trusts

Four of the best new investment trust listings

Diversify your portfolio and benefit from rising dividends with these four new investment trusts coming to the market soon.
15 Nov 2021
Is it time to remortgage your home?
Mortgages

Is it time to remortgage your home?

Banks are already starting to prepare for higher interest rates, says Alex Rankine. Should you, too?
23 Nov 2021